Scilex (SCLX) Holding announced that the U.S. FDA has acknowledged the submission of our Supplemental New Drug Application, SNDA, for ELYXYB in acute pain indication.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.